NGL Fine-Chem Limited (NSE:NGLFINE)
India
· Delayed Price · Currency is INR 998.00
-20.30 (-1.99%)
Jun 18, 2025, 3:14 PM IST
NGL Fine-Chem Revenue
In the fiscal year ending March 31, 2025, NGL Fine-Chem had annual revenue of 3.68B INR with 8.73% growth. NGL Fine-Chem had revenue of 949.71M in the quarter ending March 31, 2025, a decrease of -4.51%.
Revenue
3.68B
Revenue Growth
+8.73%
P/S Ratio
1.71
Revenue / Employee
5.40M
Employees
682
Market Cap
6.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 3.68B | 295.68M | 8.73% |
| Mar 31, 2024 | 3.39B | 606.08M | 21.79% |
| Mar 31, 2023 | 2.78B | -394.22M | -12.42% |
| Mar 31, 2022 | 3.18B | 595.28M | 23.08% |
| Mar 31, 2021 | 2.58B | 1.06B | 70.07% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 271.45B |
| Apollo Hospitals Enterprise | 217.94B |
| Mankind Pharma | 122.07B |
| Zydus Lifesciences | 232.42B |
| Aurobindo Pharma | 317.24B |
| Alkem Laboratories | 129.65B |
NGL Fine-Chem News
- 7 months ago - NGL Fine-Chem Ltd (BOM:524774) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... - GuruFocus
- 7 months ago - Q2 2025 Ngl Fine Chem Ltd Earnings Call Transcript - GuruFocus